<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31727149</PMID><DateCompleted><Year>2020</Year><Month>04</Month><Day>13</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1742-2094</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>1</Issue><PubDate><Year>2019</Year><Month>Nov</Month><Day>14</Day></PubDate></JournalIssue><Title>Journal of neuroinflammation</Title><ISOAbbreviation>J Neuroinflammation</ISOAbbreviation></Journal><ArticleTitle>Tempol improves neuroinflammation and delays motor dysfunction in a mouse model (SOD1<sup>G93A</sup>) of ALS.</ArticleTitle><Pagination><StartPage>218</StartPage><MedlinePgn>218</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">218</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12974-019-1598-x</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The development of new therapeutic strategies to treat amyotrophic lateral sclerosis (ALS) is of utmost importance. The use of cyclic nitroxides such as tempol may provide neuroprotection and improve lifespan. We investigated whether tempol (50&#x2009;mg/kg) presents therapeutic potential in SOD1<sup>G93A</sup> transgenic mice.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Tempol treatment began at the asymptomatic phase of the disease (10th week) and was administered every other day until week 14, after which it was administered twice a week until the final stage of the disease. The animals were sacrificed at week 14 (initial stage of symptoms-ISS) and at the end stage (ES) of the disease. The lumbar spinal cord of the animals was dissected and processed for use in the following techniques: Nissl staining to evaluate neuronal survival; immunohistochemistry to evaluate astrogliosis and microgliosis (ISS and ES); qRT-PCR to evaluate the expression of neurotrophic factors and pro-inflammatory cytokines (ISS); and transmission electron microscopy to evaluate the alpha-motoneurons (ES). Behavioral analyses considering the survival of animals, bodyweight loss, and Rotarod motor performance test started on week 10 and were performed every 3&#x2009;days until the end-stage of the disease.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The results revealed that treatment with tempol promoted greater neuronal survival (23%) at ISS compared to untreated animals, which was maintained until ES. The intense reactivity of astrocytes and microglia observed in vehicle animals was reduced in the lumbar spinal cords of the animals treated with tempol. In addition, the groups treated with tempol showed reduced expression of proinflammatory cytokines (IL1&#x3b2; and TNF&#x3b1;) and a three-fold decrease in the expression of TGF&#x3b2;1 at ISS compared with the group treated with vehicle.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Altogether, our results indicate that treatment with tempol has beneficial effects, delaying the onset of the disease by enhancing neuronal survival and decreasing glial cell reactivity during ALS progression in SOD1<sup>G93A</sup> mice.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chiarotto</LastName><ForeName>Gabriela Bortolan&#xe7;a</ForeName><Initials>GB</Initials><AffiliationInfo><Affiliation>Department of Structural and Functional Biology, Institute of Biology-Unicamp, Campinas, 13083-865, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cartarozzi</LastName><ForeName>Luciana Politti</ForeName><Initials>LP</Initials><AffiliationInfo><Affiliation>Department of Structural and Functional Biology, Institute of Biology-Unicamp, Campinas, 13083-865, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perez</LastName><ForeName>Matheus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Structural and Functional Biology, Institute of Biology-Unicamp, Campinas, 13083-865, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Biscola</LastName><ForeName>Natalia Perussi</ForeName><Initials>NP</Initials><AffiliationInfo><Affiliation>Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spejo</LastName><ForeName>Aline Barroso</ForeName><Initials>AB</Initials><AffiliationInfo><Affiliation>Department of Structural and Functional Biology, Institute of Biology-Unicamp, Campinas, 13083-865, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gubert</LastName><ForeName>Fernanda</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Instituto de Biof&#xed;sica Carlos Chagas Filho, Centro de Ci&#xea;ncias da Sa&#xfa;de, Sala G2-028, Universidade Federal do Rio de Janeiro, Cidade Universit&#xe1;ria, Rio de Janeiro, RJ, 21941-902, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fran&#xe7;a Junior</LastName><ForeName>Marcondes</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Faculty of Medical Sciences-Unicamp, Campinas, 13083-887, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mendez-Otero</LastName><ForeName>Ros&#xe1;lia</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Instituto de Biof&#xed;sica Carlos Chagas Filho, Centro de Ci&#xea;ncias da Sa&#xfa;de, Sala G2-028, Universidade Federal do Rio de Janeiro, Cidade Universit&#xe1;ria, Rio de Janeiro, RJ, 21941-902, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Oliveira</LastName><ForeName>Alexandre Leite Rodrigues</ForeName><Initials>ALR</Initials><Identifier Source="ORCID">0000-0003-4224-4575</Identifier><AffiliationInfo><Affiliation>Department of Structural and Functional Biology, Institute of Biology-Unicamp, Campinas, 13083-865, Brazil. alroliv@unicamp.br.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Nerve Regeneration University of Campinas-UNICAMP Cidade Universit&#xe1;ria "Zeferino Vaz", Rua Monteiro Lobato 255, Campinas, SP, 13083970, Brazil. alroliv@unicamp.br.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2014/06892-3</GrantID><Agency>Funda&#xe7;&#xe3;o de Amparo &#xe0; Pesquisa do Estado de S&#xe3;o Paulo</Agency><Country/></Grant><Grant><GrantID>2013/16168-8</GrantID><Agency>Funda&#xe7;&#xe3;o de Amparo &#xe0; Pesquisa do Estado de S&#xe3;o Paulo</Agency><Country/></Grant><Grant><GrantID>2017/02895-6</GrantID><Agency>Funda&#xe7;&#xe3;o de Amparo &#xe0; Pesquisa do Estado de S&#xe3;o Paulo</Agency><Country/></Grant><Grant><GrantID>2018/05006-0</GrantID><Agency>Funda&#xe7;&#xe3;o de Amparo &#xe0; Pesquisa do Estado de S&#xe3;o Paulo</Agency><Country/></Grant><Grant><GrantID>300553/2013-9</GrantID><Agency>Conselho Nacional de Desenvolvimento Cient&#xed;fico e Tecnol&#xf3;gico</Agency><Country/></Grant><Grant><GrantID>303085/2017-7</GrantID><Agency>Conselho Nacional de Desenvolvimento Cient&#xed;fico e Tecnol&#xf3;gico</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>11</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Neuroinflammation</MedlineTA><NlmUniqueID>101222974</NlmUniqueID><ISSNLinking>1742-2094</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003497">Cyclic N-Oxides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053583">Interleukin-1beta</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013113">Spin Labels</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>U78ZX2F65X</RegistryNumber><NameOfSubstance UI="C001803">tempol</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003497" MajorTopicYN="N">Cyclic N-Oxides</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053583" MajorTopicYN="N">Interleukin-1beta</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009048" MajorTopicYN="N">Motor Skills</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045442" MajorTopicYN="N">Rotarod Performance Test</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013113" MajorTopicYN="N">Spin Labels</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013116" MajorTopicYN="N">Spinal Cord</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS therapy</Keyword><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Neuroinflammation</Keyword><Keyword MajorTopicYN="N">Tempol</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>2</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>9</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>11</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>11</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31727149</ArticleId><ArticleId IdType="pmc">PMC6857328</ArticleId><ArticleId IdType="doi">10.1186/s12974-019-1598-x</ArticleId><ArticleId IdType="pii">10.1186/s12974-019-1598-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hardiman O, van den Berg LH, Kiernan MC. Clinical diagnosis and management of amyotrophic lateral sclerosis. Nat Rev Neurol. 2011;7(11):639&#x2013;649. doi: 10.1038/nrneurol.2011.153.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2011.153</ArticleId><ArticleId IdType="pubmed">21989247</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer LR, Culver DG, Tennant P, Davis AA, Wang M, Castellano-Sanchez A, et al. Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man. Exp Neurol. 2004;185(2):232&#x2013;240. doi: 10.1016/j.expneurol.2003.10.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2003.10.004</ArticleId><ArticleId IdType="pubmed">14736504</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A, Logroscino G, Traynor BJ, Collins J, Simeone JC, Goldstein LA, et al. Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature. Neuroepidemiology. 2013;41(2):118&#x2013;130. doi: 10.1159/000351153.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000351153</ArticleId><ArticleId IdType="pmc">PMC4049265</ArticleId><ArticleId IdType="pubmed">23860588</ArticleId></ArticleIdList></Reference><Reference><Citation>Robberecht W, Philips T. The changing scene of amyotrophic lateral sclerosis. Nat Rev Neurosci. 2013;14(4):248&#x2013;264. doi: 10.1038/nrn3430.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn3430</ArticleId><ArticleId IdType="pubmed">23463272</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O, et al. Amyotrophic lateral sclerosis. Lancet. 2011;377(9769):942&#x2013;955. doi: 10.1016/S0140-6736(10)61156-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(10)61156-7</ArticleId><ArticleId IdType="pubmed">21296405</ArticleId></ArticleIdList></Reference><Reference><Citation>Philips T, Rothstein JD. Glial cells in amyotrophic lateral sclerosis. Exp Neurol. 2014;262(Pt B):111&#x2013;120. doi: 10.1016/j.expneurol.2014.05.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2014.05.015</ArticleId><ArticleId IdType="pmc">PMC4241182</ArticleId><ArticleId IdType="pubmed">24859452</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao W, Beers DR, Appel SH. Immune-mediated mechanisms in the pathoprogression of amyotrophic lateral sclerosis. J Neuroimmune Pharmacol. 2013;8(4):888&#x2013;899. doi: 10.1007/s11481-013-9489-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11481-013-9489-x</ArticleId><ArticleId IdType="pmc">PMC4126425</ArticleId><ArticleId IdType="pubmed">23881705</ArticleId></ArticleIdList></Reference><Reference><Citation>Frakes AE, Ferraiuolo L, Haidet-Phillips AM, Schmelzer L, Braun L, Miranda CJ, et al. Microglia induce motor neuron death via the classical NF-&#x3ba;B pathway in amyotrophic lateral sclerosis. Neuron. 2014;81(5):1009&#x2013;1023. doi: 10.1016/j.neuron.2014.01.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.01.013</ArticleId><ArticleId IdType="pmc">PMC3978641</ArticleId><ArticleId IdType="pubmed">24607225</ArticleId></ArticleIdList></Reference><Reference><Citation>Murdock BJ, Bender DE, Segal BM, Feldman EL. The dual roles of immunity in ALS: injury overrides protection. Neurobiol Dis. 2015;77:1&#x2013;12. doi: 10.1016/j.nbd.2015.02.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2015.02.017</ArticleId><ArticleId IdType="pubmed">25726748</ArticleId></ArticleIdList></Reference><Reference><Citation>Vucic S, Rothstein JD, Kiernan MC. Advances in treating amyotrophic lateral sclerosis: insights from pathophysiological studies. Trends Neurosci. 2014;37(8):433&#x2013;442. doi: 10.1016/j.tins.2014.05.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2014.05.006</ArticleId><ArticleId IdType="pubmed">24927875</ArticleId></ArticleIdList></Reference><Reference><Citation>Endo F, Yamanaka K. Astrocytic TGF-&#x3b2;1: detrimental factor in ALS. Oncotarget. 2015;6(18):15728&#x2013;15729. doi: 10.18632/oncotarget.4786.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.4786</ArticleId><ArticleId IdType="pmc">PMC4599223</ArticleId><ArticleId IdType="pubmed">26164079</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamanaka K, Chun SJ, Boillee S, Fujimori-Tonou N, Yamashita H, Gutmann DH, et al. Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat Neurosci. 2008;11(3):251&#x2013;253. doi: 10.1038/nn2047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn2047</ArticleId><ArticleId IdType="pmc">PMC3137510</ArticleId><ArticleId IdType="pubmed">18246065</ArticleId></ArticleIdList></Reference><Reference><Citation>Ilieva H, Polymenidou M, Cleveland DW. Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. J Cell Biol. 2009;187(6):761&#x2013;772. doi: 10.1083/jcb.200908164.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.200908164</ArticleId><ArticleId IdType="pmc">PMC2806318</ArticleId><ArticleId IdType="pubmed">19951898</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiemermann C. Membrane-permeable radical scavengers (tempol) for shock, ischemia-reperfusion injury, and inflammation. Crit Care Med. 2003;31(1 Suppl):S76&#x2013;S84. doi: 10.1097/00003246-200301001-00011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-200301001-00011</ArticleId><ArticleId IdType="pubmed">12544980</ArticleId></ArticleIdList></Reference><Reference><Citation>Soule BP, Hyodo F, Matsumoto K, Simone NL, Cook JA, Krishna MC, et al. Therapeutic and clinical applications of nitroxide compounds. Antioxid Redox Signal. 2007;9(10):1731&#x2013;1743. doi: 10.1089/ars.2007.1722.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/ars.2007.1722</ArticleId><ArticleId IdType="pubmed">17665971</ArticleId></ArticleIdList></Reference><Reference><Citation>Augusto O, Trindade DF, Linares E, Vaz SM. Cyclic nitroxides inhibit the toxicity of nitric oxide-derived oxidants: mechanisms and implications. Anais da Academia Brasileira de Ciencias. 2008;80(1):179&#x2013;189. doi: 10.1590/S0001-37652008000100013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/S0001-37652008000100013</ArticleId><ArticleId IdType="pubmed">18345386</ArticleId></ArticleIdList></Reference><Reference><Citation>Sunkaria A, Sharma DR, Wani WY, Gill KD. Attenuation of dichlorvos-induced microglial activation and neuronal apoptosis by 4-hydroxy TEMPO. Mol Neurobiol. 2014;49(1):163&#x2013;175. doi: 10.1007/s12035-013-8508-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-013-8508-5</ArticleId><ArticleId IdType="pubmed">23884618</ArticleId></ArticleIdList></Reference><Reference><Citation>Dohare P, Hyzinski-Garcia MC, Vipani A, Bowens NH, Nalwalk JW, Feustel PJ, et al. The neuroprotective properties of the superoxide dismutase mimetic tempol correlate with its ability to reduce pathological glutamate release in a rodent model of stroke. Free Radic Biol Med. 2014;77:168&#x2013;182. doi: 10.1016/j.freeradbiomed.2014.08.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2014.08.029</ArticleId><ArticleId IdType="pmc">PMC4258548</ArticleId><ArticleId IdType="pubmed">25224033</ArticleId></ArticleIdList></Reference><Reference><Citation>Neil S, Huh J, Baronas V, Li X, McFarland HF, Cherukuri M, et al. Oral administration of the nitroxide radical TEMPOL exhibits immunomodulatory and therapeutic properties in multiple sclerosis models. Brain Behav Immun. 2017;62:332&#x2013;343. doi: 10.1016/j.bbi.2017.02.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2017.02.018</ArticleId><ArticleId IdType="pmc">PMC5496657</ArticleId><ArticleId IdType="pubmed">28238951</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali MR, Abo-Youssef AM, Messiha BA, Khattab MM. Tempol and perindopril protect against lipopolysaccharide-induced cognition impairment and amyloidogenesis by modulating brain-derived neurotropic factor, neuroinflammation and oxido-nitrosative stress. Naunyn Schmiedeberg's Arch Pharmacol. 2016;389(6):637&#x2013;656. doi: 10.1007/s00210-016-1234-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00210-016-1234-6</ArticleId><ArticleId IdType="pubmed">27026404</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipman T, Tabakman R, Lazarovici P. Neuroprotective effects of the stable nitroxide compound Tempol on 1-methyl-4-phenylpyridinium ion-induced neurotoxicity in the nerve growth factor-differentiated model of pheochromocytoma PC12 cells. Eur J Pharmacol. 2006;549(1&#x2013;3):50&#x2013;57. doi: 10.1016/j.ejphar.2006.08.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2006.08.022</ArticleId><ArticleId IdType="pubmed">16989807</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Li B, Quan MY, Li L, Chen Y, Tan GJ, et al. Mechanism of oxidative stress p38MAPK-SGK1 signaling axis in experimental autoimmune encephalomyelitis (EAE) Oncotarget. 2017;8(26):42808&#x2013;42816.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5522107</ArticleId><ArticleId IdType="pubmed">28467798</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiarotto GB, Drumond L, Cavarretto G, Bombeiro AL, de Oliveira AL. Neuroprotective effect of tempol (4 hydroxy-tempo) on neuronal death induced by sciatic nerve transection in neonatal rats. Brain Res Bull. 2014.</Citation><ArticleIdList><ArticleId IdType="pubmed">24769526</ArticleId></ArticleIdList></Reference><Reference><Citation>Edwards JN, Macdonald WA, van der Poel C, Stephenson DG. O2(*-) production at 37 degrees C plays a critical role in depressing tetanic force of isolated rat and mouse skeletal muscle. Am J Physiol Cell Physiol. 2007;293(2):C650&#x2013;C660. doi: 10.1152/ajpcell.00037.2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpcell.00037.2007</ArticleId><ArticleId IdType="pubmed">17459949</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns DP, Ali I, Rieux C, Healy J, Jasionek G, O'Halloran KD. Tempol Supplementation restores diaphragm force and metabolic enzyme activities in mdx mice. Antioxidants (Basel). 2017;6(4):1-16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5745511</ArticleId><ArticleId IdType="pubmed">29210997</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennel P, Revah F, Bohme GA, Bejuit R, Gallix P, Stutzmann JM, et al. Riluzole prolongs survival and delays muscle strength deterioration in mice with progressive motor neuronopathy (pmn) J Neurol Sci. 2000;180(1&#x2013;2):55&#x2013;61. doi: 10.1016/S0022-510X(00)00423-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(00)00423-8</ArticleId><ArticleId IdType="pubmed">11090865</ArticleId></ArticleIdList></Reference><Reference><Citation>Corti S, Nizzardo M, Nardini M, Donadoni C, Salani S, Simone C, et al. Systemic transplantation of c-kit+ cells exerts a therapeutic effect in a model of amyotrophic lateral sclerosis. Hum Mol Genet. 2010;19(19):3782&#x2013;3796. doi: 10.1093/hmg/ddq293.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddq293</ArticleId><ArticleId IdType="pubmed">20650960</ArticleId></ArticleIdList></Reference><Reference><Citation>Abercrombie M, Johnson ML. Quantitative histology of Wallerian degeneration: I. nuclear population in rabbit sciatic nerve. J Anat. 1946;80(Pt 1):37&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">20996672</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliveira AL, Thams S, Lidman O, Piehl F, H&#xf6;kfelt T, K&#xe4;rre K, et al. A role for MHC class I molecules in synaptic plasticity and regeneration of neurons after axotomy. Proc Natl Acad Sci U S A. 2004;101(51):17843&#x2013;17848. doi: 10.1073/pnas.0408154101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0408154101</ArticleId><ArticleId IdType="pmc">PMC539738</ArticleId><ArticleId IdType="pubmed">15591351</ArticleId></ArticleIdList></Reference><Reference><Citation>Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(&#x2212;Delta Delta C(T)) method. Methods. 2001;25(4):402&#x2013;408. doi: 10.1006/meth.2001.1262.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/meth.2001.1262</ArticleId><ArticleId IdType="pubmed">11846609</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, Zhao W, Liao B, Kano O, Wang J, Huang A, et al. Neuroinflammation modulates distinct regional and temporal clinical responses in ALS mice. Brain Behav Immun. 2011;25(5):1025&#x2013;1035. doi: 10.1016/j.bbi.2010.12.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2010.12.008</ArticleId><ArticleId IdType="pmc">PMC3096756</ArticleId><ArticleId IdType="pubmed">21176785</ArticleId></ArticleIdList></Reference><Reference><Citation>Harandi VM, Lindquist S, Kolan SS, Brannstrom T, Liu JX. Analysis of neurotrophic factors in limb and extraocular muscles of mouse model of amyotrophic lateral sclerosis. PLoS One. 2014;9(10):e109833. doi: 10.1371/journal.pone.0109833.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0109833</ArticleId><ArticleId IdType="pmc">PMC4198138</ArticleId><ArticleId IdType="pubmed">25334047</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xfc;st BM, Copray JC, Brouwer N, Troost D, Boddeke HW. Elevated levels of neurotrophins in human biceps brachii tissue of amyotrophic lateral sclerosis. Exp Neurol. 2002;177(2):419&#x2013;427. doi: 10.1006/exnr.2002.8011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/exnr.2002.8011</ArticleId><ArticleId IdType="pubmed">12429188</ArticleId></ArticleIdList></Reference><Reference><Citation>Endo F, Komine O, Fujimori-Tonou N, Katsuno M, Jin S, Watanabe S, et al. Astrocyte-derived TGF-&#x3b2;1 accelerates disease progression in ALS mice by interfering with the neuroprotective functions of microglia and T cells. Cell Rep. 2015;11(4):592&#x2013;604. doi: 10.1016/j.celrep.2015.03.053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2015.03.053</ArticleId><ArticleId IdType="pubmed">25892237</ArticleId></ArticleIdList></Reference><Reference><Citation>Linares E, Seixas LV, dos Prazeres JN, Ladd FV, Ladd AA, Coppi AA, et al. Tempol moderately extends survival in a hSOD1(G93A) ALS rat model by inhibiting neuronal cell loss, oxidative damage and levels of non-native hSOD1(G93A) forms. PLoS One. 2013;8(2):e55868. doi: 10.1371/journal.pone.0055868.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0055868</ArticleId><ArticleId IdType="pmc">PMC3566093</ArticleId><ArticleId IdType="pubmed">23405225</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancuso R, Oliv&#xe1;n S, Rando A, Casas C, Osta R, Navarro X. Sigma-1R agonist improves motor function and motoneuron survival in ALS mice. Neurotherapeutics. 2012;9(4):814&#x2013;826. doi: 10.1007/s13311-012-0140-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-012-0140-y</ArticleId><ArticleId IdType="pmc">PMC3480575</ArticleId><ArticleId IdType="pubmed">22935988</ArticleId></ArticleIdList></Reference><Reference><Citation>Rouaux C, Panteleeva I, Ren&#xe9; F, Gonzalez de Aguilar JL, Echaniz-Laguna A, Dupuis L, et al. Sodium valproate exerts neuroprotective effects in vivo through CREB-binding protein-dependent mechanisms but does not improve survival in an amyotrophic lateral sclerosis mouse model. J Neurosci. 2007;27(21):5535&#x2013;5545. doi: 10.1523/JNEUROSCI.1139-07.2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1139-07.2007</ArticleId><ArticleId IdType="pmc">PMC6672753</ArticleId><ArticleId IdType="pubmed">17522299</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>